| Literature DB >> 27362955 |
Ranganath Gopalakrishnan1,2, Andrey I Frolov1, Laurent Knerr1, William J Drury1, Eric Valeur1.
Abstract
Over the past decade, foldamers have progressively emerged as useful architectures to mimic secondary structures of proteins. Peptidic foldamers, consisting of various amino acid based backbones, have been the most studied from a therapeutic perspective, while polyaromatic foldamers have barely evolved from their nascency and remain perplexing for medicinal chemists due to their poor drug-like nature. Despite these limitations, this compound class may still offer opportunities to study challenging targets or provide chemical biology tools. The potential of foldamer drug candidates reaching the clinic is still a stretch. Nevertheless, advances in the field have demonstrated their potential for the discovery of next generation therapeutics. In this perspective, the current knowledge of foldamers is reviewed in a drug discovery context. Recent advances in the early phases of drug discovery including hit finding, target validation, and optimization and molecular modeling are discussed. In addition, challenges and focus areas are debated and gaps highlighted.Mesh:
Substances:
Year: 2016 PMID: 27362955 DOI: 10.1021/acs.jmedchem.6b00376
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446